ONCY
insider transactionsONCOLYTICS BIOTECH INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 10 different insiders made open-market purchases in the last 365 days, totalling $362.6K.
Net shares · 365d
+404.3K
404.3K buy · 0 sell
Net value · 365d
$362.6K
$362.6K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
14
404.3K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Chief Operating Officer
$0
145.0K sh
Own New
-
Grant·A
Kirk Look KEY
Chief Financial Officer
$0
260.0K sh
Own New
-
Grant·A
Jared Kelly KEY
Chief Executive Officer
$0
755.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
260.0K sh
Own New
-
Grant·A
Chief Technology Officer
$0
260.0K sh
Own New
-
Grant·A
Director
$0
96.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Chief Business Officer
$0
260.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
270.0K sh
Own New
-
Buy·P
Jared Kelly KEY
Chief Executive Officer
$4.8K
5.0K sh · $0.96
Own +5%
-
Buy·P
Director
$10.3K
10.0K sh · $1.03
Own +31%
-
Buy·P
Director
$33.9K
40.0K sh · $0.85
Own +8%
-
Buy·P
Director
$25.3K
30.0K sh · $0.84
Own +6%
-
Buy·P
Kirk Look KEY
Chief Financial Officer
$10.1K
12.0K sh · $0.84
Own +4%
-
Buy·P
Jared Kelly KEY
Chief Executive Officer
$24.8K
29.5K sh · $0.84
Own +37%
-
Buy·P
Chief Medical Officer
$10.0K
12.1K sh · $0.83
Own +4%
-
Buy·P
VP, Product Development
$8.3K
10.0K sh · $0.83
Own +10%
-
Buy·P
Director
$21.2K
25.0K sh · $0.85
Own +29%
-
Buy·P
Director
$30.3K
35.4K sh · $0.86
Own +83%
-
Buy·P
Director
$49.6K
60.0K sh · $0.83
Own +13%
-
Buy·P
Jared Kelly KEY
Chief Executive Officer
$4.7K
5.6K sh · $0.84
Own +8%
-
Buy·P
Chief Business Officer
$25.4K
29.6K sh · $0.86
Own +116%
-
Buy·P
Director
$103.8K
100.0K sh · $1.04
Own +27%
-
Grant·A
Director
$0
54.9K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Jonathan Rigby | Grant A | 30.0K | $0 |
| Jun 1, 2026 | Wayne Pisano | Grant A | 30.0K | $0 |
| Jun 1, 2026 | James T. Parsons | Grant A | 30.0K | $0 |
| Jun 1, 2026 | Bernd R. Seizinger | Grant A | 30.0K | $0 |
| Jun 1, 2026 | John Bearden Mcadory | Grant A | 145.0K | $0 |
| Jun 1, 2026 | Kirk Look KEY | Grant A | 260.0K | $0 |
| Jun 1, 2026 | Jared Kelly KEY | Grant A | 755.0K | $0 |
| Jun 1, 2026 | Angela Holtham | Grant A | 30.0K | $0 |
| Jun 1, 2026 | Thomas Charles Heineman | Grant A | 260.0K | $0 |
| Jun 1, 2026 | Allison Hagerman | Grant A | 260.0K | $0 |
| Jun 1, 2026 | Stephen C. Glover | Grant A | 96.0K | $0 |
| Jun 1, 2026 | Deborah Margaret Brown | Grant A | 30.0K | $0 |
| Jun 1, 2026 | Andrew Aromando | Grant A | 260.0K | $0 |
| Jun 1, 2026 | Patricia S Andrews | Grant A | 30.0K | $0 |
| Mar 25, 2026 | Patricia S Andrews | Grant A | 270.0K | $0 |
| Mar 12, 2026 | Jared Kelly KEY | Buy P | 5.0K | $4.8K |
| Mar 11, 2026 | James T. Parsons | Buy P | 10.0K | $10.3K |
| Feb 12, 2026 | Bernd R. Seizinger | Buy P | 40.0K | $33.9K |
| Feb 12, 2026 | Wayne Pisano | Buy P | 30.0K | $25.3K |
| Feb 12, 2026 | Kirk Look KEY | Buy P | 12.0K | $10.1K |
| Feb 12, 2026 | Jared Kelly KEY | Buy P | 29.5K | $24.8K |
| Feb 12, 2026 | Thomas Charles Heineman | Buy P | 12.1K | $10.0K |
| Feb 12, 2026 | Allison Hagerman | Buy P | 10.0K | $8.3K |
| Feb 12, 2026 | Deborah Margaret Brown | Buy P | 25.0K | $21.2K |
| Feb 12, 2026 | Patricia S Andrews | Buy P | 35.4K | $30.3K |
| Feb 11, 2026 | Bernd R. Seizinger | Buy P | 60.0K | $49.6K |
| Feb 11, 2026 | Jared Kelly KEY | Buy P | 5.6K | $4.7K |
| Feb 11, 2026 | Andrew Aromando | Buy P | 29.6K | $25.4K |
| Jan 16, 2026 | Bernd R. Seizinger | Buy P | 100.0K | $103.8K |
| Jan 12, 2026 | Stephen C. Glover | Grant A | 54.9K | $0 |
About ONCY insider trading
This page tracks insider transactions for ONCOLYTICS BIOTECH INC (ONCY) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.